Stakeholders Surprised As French Biosimilar Substitution Changes Tack
France’s Health Ministry And ANSM Agency Deviate From Approach Agreed In Consultation
Executive Summary
The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.
You may also be interested in...
Finland Sees Progress On Biosimilar Substitution Plans
Updated plans to implement pharmacy-level biosimilar substitution in Finland have been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.
Finland Sees Progress On Biosimilar Substitution Plans
Updated plans to implement pharmacy-level biosimilar substitution in Finland have just been published by a parliamentary health committee ahead of expected formal approval within weeks, reflecting certain industry criticisms that have now been taken on board.
Finnish Biosimilar Substitution Proposals Get Pushback From Industry
Finnish government proposals to introduce pharmacy-level substitution for biosimilars have been criticized by the country’s generics and biosimilars industry association.